Evaluation of the applicability of BI-RADS® MRI for the interpretation of contrast-enhanced digital mammography

被引:14
|
作者
Travieso-Aja, M. M. [1 ]
Maldonado-Saluzzi, D. [1 ]
Naranjo-Santana, P. [1 ]
Fernandez-Ruiz, C. [1 ]
Severino-Rondon, W. [1 ]
Rodriguez Rodriguez, M. [1 ]
Luzardo, O. P. [2 ,3 ]
机构
[1] Grp Hosp San Roque, Dept Radiol, Div Diagnost Mama, Las Palmas Gran Canaria, Spain
[2] Univ Las Palmas Gran Canaria, Inst Invest Biomed & Sanitarias IUIBS, Las Palmas Gran Canaria, Spain
[3] Inst Salud Carlos III, Ctr Invest Biomed Red Obesidad & Nutr CIBERObn, Madrid, Spain
来源
RADIOLOGIA | 2019年 / 61卷 / 06期
关键词
Cancer de mama; Patologia mamaria; Contrast-enhanced mammography; Breast magnetic resonance imaging; BI-RADS (R); CATEGORIZE BREAST MRI; RADS 5TH EDITION; SPECTRAL MAMMOGRAPHY; GRADING SYSTEM; DESCRIPTORS; CANCER; PROBABILITY; PERFORMANCE; TERMS; SIZE;
D O I
10.1016/j.rx.2019.05.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To determine the usefulness of BI-RADS (R) MRI for the morphological description and categorization of images obtained with contrast-enhanced digital mammography in comparison with the final diagnosis. Material and methods: We included patients who had palpable breast lesions, those who needed clarification regarding abnormalities identified with another imaging technique, and those which needed a complementary evaluation of heterogeneously dense breast parenchyma. Three radiologists working independently used a template with the BI-RADS (R) MRI qualitative descriptors to evaluate the breast lesions studied with contrast-enhanced digital mammography. In a second phase, two other experienced radiologists reached a consensus about discrepant interpretations. Readers also classified each lesion (both benign and malignant lesions) on the BI-RADS (R) scale (1 - 5). All the results were compared with the real state of disease (determined by the appropriate gold standard for each type of lesion), and the statistical significance was assessed with the chi-square test. Results: A total of 218 benign lesions and 426 malignant lesions were included. The interobserver agreement among the three radiologists was high (Fleiss-Cohen kappa =0.805; 95% CI: 0.728-0.837). Similarly to what has been reported about breast MRI, on contrast-enhanced digital mammography, malignant lesions with mass effect tended to have an irregular shape with spiculated or ill-defined margins and a pattern of intense and heterogeneous enhancement (p <0.001). Nevertheless, unlike on breast MRI, ring enhancement was not an independent criterion of malignancy on contrast-enhanced digital mammography. For lesions without a mass effect, the only significant descriptor was the intensity of contrast material uptake (p < 0.05). Applying the BI-RADS (R) MRI material to contrast-enhanced digital mammography images enabled the correct classification of 85% of lesions in the benign categories (BI-RADS 1 and BI-RADS 2 and 3 lesions) and of 93% of the lesions in the malignant categories (BI-RADS 4-5); these values are similar to those reported for breast MRI. Conclusions: The morphological descriptors used in BI-RADS (R) MRI can be applied to the morphological analysis of breast lesions studied with contrast-enhanced digital mammography. The partial discrepancies in the interpretation did not influence the final BI-RADS (R) score, and the score enabled good differentiation between benign and malignant lesions. (C) 2019 SERAM. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:477 / 488
页数:12
相关论文
共 50 条
  • [41] Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy
    Clauser, Paola
    Krug, Barbara
    Bickel, Hubert
    Dietzel, Matthias
    Pinker, Katja
    Neuhaus, Victor-Frederic
    Marino, Maria Adele
    Moschetta, Marco
    Troiano, Nicoletta
    Helbich, Thomas H.
    Baltzer, Pascal A. T.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1941 - 1948
  • [42] TR-BI-RADS: a novel dataset for BI-RADS based mammography classification
    Mustafa Mahir Ülgü
    Cemil Zalluhoglu
    Suayip Birinci
    Yasin Yarbay
    Ebru Akcapinar Sezer
    Neural Computing and Applications, 2024, 36 : 3699 - 3709
  • [43] Limited value of scintimammography and contrast-enhanced MRI in the evaluation of microcalcification detected by mammography
    Tiling, R
    Khalkhali, I
    Sommer, H
    Linke, R
    Moser, R
    Willemsen, F
    Pfluger, T
    Tatsch, K
    Hahn, K
    NUCLEAR MEDICINE COMMUNICATIONS, 1998, 19 (01) : 55 - 62
  • [44] Contrast-enhanced Mammography and Breast MRI: Friends or Foes?
    Lobbes, Marc B. I.
    Jochelson, Maxine S.
    Neeter, Lidewij M. F. H.
    Nelemans, Patricia J.
    RADIOLOGY, 2023, 307 (01)
  • [45] Contrast-enhanced spectral mammography in patients with MRI contraindications
    Richter, Vivien
    Hatterman, Valerie
    Preibsch, Heike
    Bahrs, Sonja D.
    Hahn, Markus
    Nikolaou, Konstantin
    Wiesinger, Benjamin
    ACTA RADIOLOGICA, 2018, 59 (07) : 798 - 805
  • [46] Automated classification of BI-RADS in textual mammography reports
    Boroumandzadeh, Mostafa
    Parvinnia, Elham
    TURKISH JOURNAL OF ELECTRICAL ENGINEERING AND COMPUTER SCIENCES, 2021, 29 (02) : 632 - 647
  • [47] Mammography Image BI-RADS Classification Using OHPLall
    Vanderheyden, Bob
    Xie, Ying
    2020 IEEE SIXTH INTERNATIONAL CONFERENCE ON BIG DATA COMPUTING SERVICE AND APPLICATIONS (BIGDATASERVICE 2020), 2020, : 121 - 128
  • [48] Automated classification of BI-RADS in textual mammography reports
    Boroumandzadeh M.
    Parvinnia E.
    Turkish Journal of Electrical Engineering and Computer Sciences, 2021, 29 (02): : 632 - 647
  • [49] Implementing the advantages of contrast-enhanced mammography and contrast-enhanced breast MRI in breast cancer staging
    Fallenberg, Eva M.
    EUROPEAN RADIOLOGY, 2025, 35 (01) : 160 - 162
  • [50] BIRADS 4 breast lesions: comparison of contrast-enhanced spectral mammography and contrast-enhanced MRI
    Yasin R.
    El Ghany E.A.
    Egyptian Journal of Radiology and Nuclear Medicine, 50 (1):